Introduction
Hematopoietic SCT may provide a curative treatment for a subgroup of patients suffering from various hematological malignancies. [2] [3] [4] The success of SCT mainly depends on the speed of cellular immune reconstitution after transplantation. 1, 5 As such, a fast immune recovery is of central importance for both, the prevention of serious infections and the attack of residual malignant cells to prevent a relapse. We and other investigators were able to show that a rapid immune reconstitution is associated with lower TRM and a better survival post SCT. 1, 6 In a univariate analysis, we had previously observed a significantly higher number of survivors among those patients whose CD3 þ CD8 þ absolute counts increased above the fifth percentile of age-matched normal levels during the firstyear post SCT compared with patients who never reached these levels. 1 Therefore, a slow immune reconstitution can be regarded as an indicator defining patient groups with a high risk of relapse and an increased susceptibility to viral and fungal infections. 7 The introduction of adoptive cell therapy to support the recipient's immune system can be effective with regard to treatment outcome for patients within the high-risk group. 6 Hence, a classification of patients into high-risk and low-risk groups with regard to cell reconstitution might be a helpful strategy to identify patients that might benefit from additional cell therapies such as donor lymphocyte infusions.
The human immune system is a complex network of interactions between various leukocyte subpopulations. Until now only univariate analyses had been carried out, that cannot reflect the complex interactions between the sub-populations of the immune system. Furthermore, the relative and absolute sizes of leukocyte sub-populations vary during childhood. 8, 9 Therefore, age-matched reference values are required when analyzing immune reconstitution after SCT.
Multivariate approaches may provide suitable strategies to design models, which may better represent the complicated cell interactions of the immune system. To divide patients undergoing allo-SCT into risk groups, we generated a multivariate model on the basis of normal leukocyte sub-population values of children and young adults. On the basis of this new model we further generated age-matched reference domains and classified the immune reconstitution of pediatric patients suffering from leukemia after SCT with regard to survival and compared this with our previous univariate analysis 1 in the same patient cohort.
Patients and methods

Study design
To improve the reliability of classification into a high-risk and a low-risk group with regard to cellular immune reconstitution post SCT, we replaced our univariate analysis 1 by a multivariate approach. First we generated an ellipsoidal reference domain from a new three-component multivariate model on the basis of our age-matched leukocyte sub-population reference values of 100 children and adolescents hospitalized for minor elective surgery. 9 Afterwards this ellipsoidal domain was used to classify the immune reconstitution of 32 pediatric patients post SCT and to relate reconstitution to overall survival (OS). On the basis of the classification result the patients were subdivided into a high-risk and a low-risk group. Finally, the results of the multivariate approach were compared with our previously published univariate analysis 1 in the same cohort of 32 patients, both with an increased median follow-up of 5 years.
Model description and statistics
For reference-model generation a data set was used which includes eight leukocyte normal-value subgroups of 100 healthy children and adolescents, 9 respectively. It contained absolute cell counts for leukocytes, CD14 þ monocytes, lymphocytes, CD3
þ natural killer cells and CD19 þ B cells. In all donors there was no indication of inflammation or other impacts, which may have influenced the leukocyte sub-population counts. To preserve age dependency, the data were pre-processed by taking log(x þ 1) and subtracting an age-dependent mean. The data were scaled to unit variance, so that the data, which have small variance are not dominated by variables with high variance. Patient and reference data were preprocessed in the same fashion. Principal component analysis (PCA) 10 was then used before classification for dimensionality reduction from eight to three dimensions. been applied for dimensionality reduction from eight to three dimensions. To preserve age dependency, the data were pre-processed by taking log(x þ 1) and subtracting an age-dependent mean. (a) Three-dimensional coordinate system embedding the reference ellipsoid. The first component p(1) essentially describes lymphocytes, CD3 Figure 1c .
Age-dependent means were subtracted applying R statistical software, version 2.61 (open source software, http://www.r-project.org), multivariate analyses were carried out with the SIMCA-P þ software version 12 (Umetrics, Umea˚, Sweden, http://www.umetrics.com/ default.asp/pagename/software_simcap/c/3), Kaplan-Meier survival curves were generated with GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA, www.graphpad.com). All the P-values shown here are calculated using log-rank 11 test which was also applied in our previous univariate analysis. 1 All P-values o0.05 were regarded as significant. For confirmation, P-values were also checked employing Fisher's exact test.
Patients and grafts
Immune reconstitution was monitored regularly in 32 pediatric patients post SCT. Informed consent was obtained from all patients/parents and the study was approved by the local ethic committee. Indications for transplantation were high-risk acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia and myelodysplastic syndrome ( Table 1 ). The conditioning regimes varied according to the underlying disease. All patients were monitored over a time period of at least 6 months. Median follow-up was 5 years. Patient's age at the time of transplantation varied between 2 1 2 and 23 years, with a median age of 9 1 2 years. Two patients within the 32 received a second transplant from a haplo-identical donor after relapse of their disease after a first therapy with stem cells of an HLA-identical donor. For these two patients only the immune monitoring after the second transplantation was included.
Stem cell sources consisted of unmanipulated PBSC (n ¼ 5), unmanipulated BM (n ¼ 13), CD34
þ -selected PBSC (n ¼ 13) and CD3/CD19-depleted PBSC (n ¼ 1) from matched and mismatched family or matched unrelated donors. PBSC were mobilized with human recombinant G-CSF over a time period of 5 days before leukapheresis. CD34
þ -selected grafts and the CD3/CD19-depleted graft were purified immunomagnetically on a CliniMacs device (Miltenyi Biotec, Bergisch Gladbach, Germany) obeying good manufacturing practice with a final single-platform flow-cytometric quality control, as described previously.
1,12,13
Assessment of leukocyte sub-populations Leukocyte sub-populations were analyzed by four-and five-color flow-cytometric analyses on an EpicsXL or on a FC500 (Beckman Coulter, Krefeld, Germany), respectively. Within the first 3 months after transplantation EDTA samples of peripheral blood from the patients were taken weekly, from the beginning of month 4 to month 6 samples were taken twice a month, followed by a period of monthly blood analysis from month 7 to 1 year post transplant. From this time point up to 4 years after transplant, patient samples were collected every 3 months. The absolute nos.
þ natural killer cells and CD19 þ B cells in the blood samples were determined in a lyseno-wash procedure as described previously. 1,9 Briefly, two tubes with 100 ml of peripheral blood were labeled with tetraCHROME combinational mAb reagents for CD45/ CD4/CD8/CD3 and CD45/CD56/CD19/CD3 conjugated with FITC, phycoerythrin, phycoerythrin texas red, phycoerythrin-cyanine 5.1, respectively. Monocytes were detected by adding phycoerythrin-cyanine 7 labeled CD14 monoclonal antibodies to the first tube or by a separate CD45/CD14 analysis. All reagents are purchased from Beckman Coulter Immunotech (Marseilles, France). Absolute cell counts are calculated from the percentage values using a dual-platform approach.
Flow-Set Fluorospheres served to set up the photomultiplier tube values weekly. Stained Cyto-Comp cells were applied to compensate the fluorescence overlap. The flow-cytometer optical alignment and the fluidic stability were tested daily using Flow-Check Fluorospheres and Immuno-Trol control cells were applied for verification. This approach was used for leukocyte subset analysis for the healthy controls and for patient sample analysis. For model generation as well as for classification only absolute values have been used.
Results
Reference model of normal leukocyte sub-population values
On the basis of reference values of 100 healthy children and adolescents a multivariate model was built, which defines an age-matched range of normal leukocyte sub-population values. In comparison to non-parametric reference values established by Comans-Bitter et al. 8 based on 429 children, univariate reference intervals obtained from the 100 children and young adults used for model generation herein have been shown to be equivalent. 9 Our model is a three component multivariate PCAmodel with a 99% confidence region for the PCA-scores, that is of ellipsoidal shape and is embedded in a threedimensional coordinate system. The first component summarizes leukocytes, lymphocytes, CD3 Owing to the use of a 99% confidence level, all of the 100 reference value data sets are indeed enclosed within the reference ellipsoid (Figures 1b and c) .
Characteristic parameters and clinical follow-up after SCT A total of 32 pediatric patients undergoing allo-SCT were assessed for cellular immune reconstitution. Successful engraftment was observed in all children with a median follow-up of 5 years (Table 1 ). In total, 16 out of 32 Classification of immune reconstitution post SCT Using the multivariate model from the 100 healthy children and adolescents, the progress of immune reconstitution of 32 pediatric patients after SCT is classified. A patient is classified positive (low-risk group) if he/she reaches the reference ellipsoid on or before day 200 after transplant and stays within the ellipsoid for at least 1 month. Negative classification (high-risk group) necessitates that a patient's leukocyte sub-population values never reach or do not remain within the ellipsoid of normal values. As an example the immune reconstitution of patient #24 (Table 1) is displayed (Figures 2a-c) . The patient reaches the ellipsoid of normal values at day 200 and stays inside from that day on. This progress of immune reconstitution is classified as positive by applying the classification criterion described. As a high-risk example the immune reconstitution of patient #27 is selected (Figures 2b and c) . He never reaches the reference ellipsoid and dies 194 days post SCT.
Reconstitution of leukocyte sub-populations with regard to OS
On the basis of the above mentioned classification rules, we built two patient groups, a low-risk group including all the patients that reached the reference ellipsoid by day 200 and stayed within for at least 1 month and a high-risk group containing all the patients who did not reach the range of reference values or did not stay within it. We detected a significantly higher number of long-time survivors among the low-risk group (13 survivors out of 18 patients) compared with the high-risk group (3 survivors out of 14 patients) with P ¼ 0.001. A second retrospective classification at day 300 post SCT resulted in Po0.0001 with all patients dying which are in high-risk group (no survivor out of 11 patients) compared with 16 survivors out of 21 patients in the low-risk group (Figure 3) . Unfortunately, 10 patients in the cohort did not reach the classification date of 300-days post SCT. Therefore, for a prognostic conclusion at day 300, the exclusion of these patients resulted in an equal P-value of Po0.0001. Three patients (#5, #12 and #32) assessed to be in the high-risk group evaluating the data at day 200, finally reached the reference ellipsoid by day 300 post SCT. Among these 3 patients, one had an impaired immune reconstitution, the second patient had an acute GVHD (#12) and the third patient received secondary haplo-identical transplantation with CD3/ CD19-depleted stem cells, because of a second relapse of his illness (#32). Five patients reached the reference ellipsoid on or before day 200 post SCT, but died. Three of them (#3, #21 and #22) left the reference space long before they died. No major differences were detected comparing parameters between the low-risk and the high-risk groups. The underlying diseases were clustered into four groups ( (1) acute lymphoblastic leukemia CR1 and CR2; (2) acute lymphoblastic leukemia CR3 and NR; (3) acute myeloid
Monitoring time (days following SCT) tPS [1] tPS [2] tPS [3] T 2 range values tPS [1] tPS [3] tPS [2] leukemia; and (4) MDS, JMML and chronic lymphocytic leukemia). The four categories were nearly equally distributed over the risk groups. The same applies to the stem cell donor types matched family donor, matched unrelated donor and mismatched family donor. It is to be noted that in patients receiving unmanipulated grafts (n ¼ 18) all four patients without CY survived, whereas about two-third of the patients receiving CY died. Donor lymphocyte infusion was applied in 7 out of 32 patients (22%), 3 of them were in the high-risk and 4 in the low-risk group. Except one all of these patients died. In all, 21 out of 32 patients (66%) received steroids. Of these patients 10 were in the high-risk group at day 200 and 8 were in the high-risk group at day 300 after transplant. An acute GVHD developed in 9 out of 32 patients (28%), 5 of them were in high-risk group at day 200 and 4 of them were in high-risk group at day 300 post SCT. Five of these patients died. Three of them by virtue of their GVHD and two because of GVHD combined with a relapse of their disease.
Significance of our new multivariate immune reconstitution model
We finally compared our new multivariate approach with the previous univariate analysis. 1 Using our new multivariate ellipsoidal model we present herein, we were able to increase the significance level to Po0.0001 evaluating the data at day 300 post SCT. In contrast, our previous univariate study resulted in Po0.001 only, for both, a median follow-up of 4 years, as already published 1 and our new update with a median follow-up of 5 years. In the univariate study we analyzed the number of long-time survivors among those patients who reached the fifth percentile of age-matched normal CD3 þ CD8 þ values within the first-year post SCT.
Discussion
A rapid immune reconstitution post SCT is of central importance to protect the patients from relapse and severe infections. 1, 6, 14, 15 As such, an adequate immune recovery can effectively eliminate a recipient's residual malignant cells in the early phase post SCT, thereby reducing the risk of relapse. 16 Patients with delayed immune reconstitution show an enhanced probability of relapse and late infections remain the major cause of non-relapse mortality. 17 In patients with impaired immune reconstitution the introduction of additional cell therapies may be helpful to augment the immune functions. 6 To date, intervention in pediatric patients has mainly been based on minimal residual disease diagnostic and donor/recipient chimerism. 18 Unfortunately, some of the patients already exhibit a manifest relapse at the time, when an increased autologous minimal residual disease/chimerism level is detectable. At this point there is often a delay in therapeutic intervention. Therefore, adequate models to identify high-risk patients are necessary.
Within this work we show an approach to classify pediatric patients suffering from leukemia into high-risk and low-risk groups based on the speed of cellular immune reconstitution post SCT. To this end we pre-processed and age-matched data from various leukocyte sub-populations of healthy children and young adults, 9 then generated a new three-component multivariate model with an ellipsoidal confidence region. Next we analyzed in a cohort of 32 pediatric patients with leukemia whether they were able to reach the ellipsoid of age-matched leukocyte subpopulation values. Patients who enter our ellipsoid of normal leukocyte subpopulation values on or before day 200 and 300 post SCT (low-risk group) have a superior chance of becoming long-time survivors compared with patients who do not reach the range of age-matched normal values (high-risk group).
Using our new multivariate approach we were able to increase the significance level at day 300 post SCT (Po0.0001) compared with an evaluation of the updated immune reconstitution data in the same patient cohort using our previously published univariate model 1 at day 365 post SCT (Po0.001). This implies that multivariate solutions are more suitable to reflect the complex interactions of the human immune system than univariate solutions are. Within our new multivariate study we analyzed different time points (200, 300 and 365 days post SCT). As we did not find differences within the classification results at day 300 and 365 (data not shown), results were only presented for 200 and 300 days. Introducing prophylactic donor lymphocyte infusions may be beneficial in patients within the high-risk group to overcome the susceptibility for relapse or infectious complications. Nevertheless, prophylactic donor lymphocyte infusion carries a risk of severe GVHD and GVHDinduced mortality. 6 Therefore, intensive studies on large patient groups are needed before such a model defining the best time points for therapeutically intervention prior to the appearance of clinical events may be achieved. In addition such a 'tailored therapy' may also be applied for compassing purified donor natural killer cell application or T cell applications with specificity to viral or fungal infections. 19, 20 The progress of immune reconstitution is different in each patient. This leads to difficulties defining time points when the patients' immune cells should have reached the age-matched normal range. For that reason we evaluated the immune reconstitution of all patients included in this study at the time points 200 and 300 post SCT. We have discovered that three long-time survivors have not reached the reference ellipsoid at day 200, but at day 300 post transplant. To define an appropriate time frame for classification especially for earlier time points, an evaluation of a larger set of patient immune reconstitution data is needed. Survival P could be estimated using a multivariate, penalized version of the Cox's proportional hazard model for time-dependent collinear covariates, the leukocyte subpopulations. 21, 22 To date, our work was undertaken to generate a new multivariate model as opposed to multiple univariate models for a first proof of principle towards a more reliable classification into high-and low-risk patients.
Five of our patients reached the reference ellipsoid of normal values at day 200 post SCT, but died. Three out of these patients left the reference space weeks before they died. Therefore, further attention should be paid to an exit of the reference space after primary achievement. Again, in order to establish significant correlation between this possible immune 'deterioration' and relapse or infection mortality more patients are needed who re-exit the ellipsoidal reference region. Extrapolating from the 32 patients, of whom 3 re-exited, at least 200 patients would be needed to study the phenomenon. Unfortunately, in our study the cohort of patients was too small to achieve significant results concerning this question.
The data set we used for model generation consisted of leukocyte sub-population values of 100 healthy children and adolescents which were in accordance to lymphocyte subsets given by Comans-Bitter et al. 8 for 429 healthy children. 9 Literature unfortunately lacks information about additional sufficient leukocyte subgroups like naı¨ve, effector-and central memory T cells in healthy children. When available these additional age-matched leukocyte subgroups may give rise to further improvement of our new multivariate ellipsoidal model for the classification of patients into high-and low-risk groups post SCT.
Previously we could demonstrate in a univariate analysis a significantly higher number of survivors among patients whose CD3
þ CD8 þ cytotoxic T cells rose above the fifth percentile of age-matched normal values during the firstyear post SCT. 1 þ CD8 þ cytotoxic T cells can be compensated by low values of the other cell sub-populations. The method of principle component analysis, which we applied for dimensionality reduction herein, is a standard technology. In our application it retains the most important aspects of the reference data set on the basis of variance estimation. This offers the possibility to reduce dimensionality from eight to three. The cluster of leukocytes, lymphocytes, CD3
þ cytotoxic T cells and CD19 þ B cells seems to have the most redundant information and can, therefore, be mainly described by the first axis. There is a strong relation between helper T cells and cytotoxic T cells as subgroups of the overall CD3 þ T cells. In addition, CD3 þ reconstitution after SCT often parallels the whole lymphocyte reconstitution, whereas other lymphocyte sub-populations like natural killer-cells are normally recovered as early as 1-month post SCT. 1 However, with regard to our previous work, 1 in a next step, the multivariate model could be enhanced by using PCA directly on patient data in order to better understand the role of CD3 þ CD8 þ cytotoxic T cells and their interactions with the other cell populations. An alternative and supplementary approach would also be to assign weights to the individual cell population. The high impact of immune reconstitution with regard to survival could also be shown in a study of Kim et al. 6 showing a significant difference in OS between patients with a fast reconstitution of lymphocytes compared with patients with a slow recovery. In an overall cohort of 82 adult patients they were able to define day 21 post SCT as an interesting time point to differ between high-and low-risk patients. Their model used a multiple Cox's proportional hazard regression to estimate survival for several time-independent covariates, including ALC (absolute lymphocyte count) at day 21. However, no methodological safe guards against lurking collinearities were given.
Finally in our study, a severe limitation is given by the fact that within the first weeks after transplantation the patients rarely reach the lower limit of age-matched leukocyte sub-population values, typically some 2-6 months are needed to reach the ellipsoid. In addition, the progress of immune reconstitution in early weeks is influenced by many different factors, 23 such as the stem cell source, the amount of CD34 þ stem cells and CD3 þ T cells in the graft, 1, 14, 15, [24] [25] [26] [27] patient age, 16, 28 the CMV status 14, 29, 30 and the GVHD prophylaxis or treatment. 31 These facts also support the idea to generate a model on the basis of immune reconstitution data of long-time survivors. Such a model could represent the progress of immune reconstitution post SCT much better than a reference model based on healthy donors, but again this requires large data sets, in the order of the size of the reference set of healthy children of long-time survivors.
In conclusion, we could show for the first time that multivariate immune reconstitution studies can be applied to develop predictive markers concerning survival with the future aim of applying immunotherapeutic intervention before the occurrence of relapse or life-threatening infections.
The results of our pilot study indicate that a model-based classification of patients into low-risk and high-risk groups on the basis of the immune reconstitution is possible. A new multivariate PCA-model was established that in some respects is superior to previous univariate analyses. Combined with the clinical observation, the classification into the high-risk group may assist as a predictor for complications. Our preliminary results should be confirmed in a larger study using both, increased number of patients and an enhanced multivariate modeling technique with the future goal of offering a multivariate solution for a more reliable risk-estimation.
